Opened 2007. Provides office space, mentorship, and links to Limerick's industry network for medtech, biotech, and digital media startups; supported 50+ firms.
Notable alumni include Stokes Bio. Scope: Regional (Mid-West Ireland).
Limerick, Ireland
Incubator
/ireland/incubator/hartnett-enterprise-acceleration-centre
Warsaw-based medtech startup developing AptaSense, a bedside analyzer for near real-time therapeutic drug monitoring. The platform uses disposable strips to measure antibiotic and protein levels in around one minute to support precise dosing in sepsis and critical care.
Azafaros is a clinical-stage biotech company developing oral therapies for rare genetic metabolic disorders, including lysosomal diseases. Its lead development strategy focuses on compounds designed to cross the blood-brain barrier and address severe neurological progression in underserved pediatric conditions.
Bioptimus is the self-proclaimed "Mistral of Biology," spun out in early 2024 by a team of alumni from Google DeepMind and Owkin, including CEO Jean-Philippe Vert. The company is building what it calls the first universal foundation model for biology. Where large language models were trained on text to learn human language, Bioptimus trains on biological data—DNA sequences, protein structures, cellular imagery, and clinical phenotypes—to infer the underlying rules of life. The ambition is not just better predictions but a unified biological reasoning layer that can simulate outcomes before expensive lab work happens. By 2026, Bioptimus has moved from a research thesis to early commercial traction. After a $41M Series A in 2025, the company released its first commercial model that can predict how a specific molecule will interact with a human cell with unusually high accuracy. This enables in-silico screening that reduces wet-lab costs and improves hit rates for drug discovery. French pharma leaders such as Sanofi have begun using these models to prioritize compounds and compress early-stage discovery timelines. The product value is immediate: fewer failed experiments, faster candidate selection, and deeper mechanistic insight. Bioptimus' roadmap focuses on "multi-scale biology," connecting the micro level (genomics and proteomics) to the macro level (patient outcomes and clinical data). Rather than being limited to protein folding, the models aim to bridge across data modalities so a genetic mutation can be linked to disease pathways, tissue behavior, and potential therapeutic interventions. This requires data breadth and regulatory trust, and Bioptimus is building a defensive moat through European data sovereignty. It leverages partnerships with European research hospitals and biobanks to access high-quality patient data that is difficult for US competitors to acquire under GDPR constraints. That compliance burden becomes a competitive advantage: safer access, better provenance, and stronger alignment with European health data governance. The company remains deeply embedded in the Paris ecosystem. It was incubated inside Owkin before spinning out, maintains a presence around Station F, and benefits from the cross-pollination between French AI and biotech communities. Its investor base reflects that positioning: Sofinnova Partners, Bpifrance, Cathay Innovation, Xavier Niel, and Frst provide a blend of life-science expertise, sovereign capital, and deep-tech conviction. In 2026, Bioptimus is the clearest European bet that foundation models can unlock biology at scale—and a contender to become the default AI layer for drug discovery in Europe.
Generative protein design platform helping scientists engineer new vaccines, therapeutics, and materials.
Dawn Health develops regulated software-as-a-medical-device products with pharmaceutical and life-science partners. The company builds digital therapeutics and companion applications for adherence, remote monitoring, and real-world clinical data capture in regulated settings.
Distalmotion develops Dexter, a hybrid robotic surgery platform intended to make robotic-assisted minimally invasive procedures more accessible to a broader hospital base. The system allows surgeons to move between robotic and laparoscopic workflows during operations to improve flexibility and operating-room integration.
Checking login status...
Loading comments...